首页/数据集/Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive non-segmental vitiligo

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive non-segmental vitiligo

NIAID Data Ecosystem2026-05-02 收录

白癜风治疗

JAK抑制剂治疗

数据链接：

https://data.mendeley.com/datasets/5gp4xy63xv 数据链接链接失效反馈

官方服务：

资源简介：

Efficacy of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive non-segmental vitiligo

应用场景：

创建时间：

2025-06-05

副作用监测

白癜风治疗

Introduction: Tacrolimus is widely used in treating vitiligo. Drug-induced hypertrichosis is a well-known side effect of cyclosporine. It is less commonly associated with tacrolimus or with topical ca

DataCite Commons2025-04-05 更新80

Demographic and clinical data of vitiligo patients undergoing transplantation.

白癜风治疗

患者临床数据

Demographic and clinical data of vitiligo patients undergoing transplantation.

Figshare2015-12-02 更新50

Oral upadacitinib combined with 308-nm excimer light for refractory progressive vitiligo in children and adults：A prospective observational study

白癜风治疗

药物光疗联合疗法

Figure 2. Representative clinical photos of refractory vitiligo patients at the baseline and 12-week follow-up. Patient 2 before (A) and after (B) treatment. Patient 13 before (C) and after (D) treatm

NIAID Data Ecosystem20

Supplementary Data for Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: a non-inferiority randomized controlled trial

白癜风治疗

临床试验

Mendeley Supplementary Figure 1. Proportion of patients achieving disease arrest in both treatment arms at each visit (per-protocol analysis) Mendeley Supplementary Figure 2. Change in proportion of p

Mendeley Data2024-03-27 更新70

Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis

白癜风治疗

JAK抑制剂治疗

Vitiligo is a chronic autoimmune disease causing skin depigmentation and psychosocial issues. Non-segmental vitiligo often shows limited response to standard therapies. The IFN-γ–JAK–STAT pathway play

Taylor & Francis Group2025-12-27 更新30

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive non-segmental vitiligo

资源简介：

相关数据集